Introduction: The Titin Paradox in Clinical Practice
Truncating variants in the titin gene (TTNtv) represent the most prevalent genetic substrate for dilated cardiomyopathy (DCM), accounting for approximately 15% to 25% of sporadic cases and up to 30% of familial cases. Titin, the largest protein in the human body, serves as a molecular spring within the cardiac sarcomere, providing structural integrity and mediating passive stiffness. However, the clinical interpretation of TTNtv remains a significant challenge. These variants are found in approximately 1% of the general population, many of whom remain asymptomatic throughout their lives. This phenomenon of incomplete penetrance and variable expressivity suggests that the presence of a TTNtv is often a necessary but insufficient condition for the development of overt heart failure.
Clinicians frequently encounter a diagnostic dilemma: how to manage an asymptomatic individual who carries a TTNtv identified through family screening or as an incidental finding. Recent research published in the European Heart Journal by Johnson et al. provides critical insights into this problem, identifying the specific clinical and environmental ‘second hits’ that drive the transition from a genetic predisposition to clinical DCM.
